On December 8, Bob Doll, Crossmark Global Investments CEO and CIO, joined CNBC’s ‘Squawk on the Street’ to discuss the latest market trends and his expectations for the Fed. Doll believes that the current situation is a high-risk bull market and emphasized that these words were chosen carefully. He explained the bull market component by noting that the path of least resistance for stocks is higher, especially when the Fed is cutting rates and earnings estimates are rising, which rarely results in stocks going down. He concluded the bull part by saying one has to be invested. The high-risk part, according to Doll, is due to the speculation taking place, high valuations, and other factors, leading him to expect persistent volatility.
In addressing the Fed specifically, Doll pointed out the extreme shifts in the market’s perceived probability of a rate cut, which has fluctuated wildly from an 80% chance to 30%, and then up to 90%, and suggested that nobody knows for certain what will happen, although it seems like they will lower rates. Doll discussed the inherent complexity of the situation: on one hand, doves might argue the Fed should hustle down to neutral rates, supported by an expectation of underlying disinflation next year. On the other hand, he noted the unusual nature of the Fed potentially cutting rates by a total of 1.75% in 15 months by the upcoming Wednesday without a recession really in sight. Doll characterized this as a tricky moment and called the 1.75% cut against no recession bizarre.
That being said, we’re here with a list of the 11 high short interest stocks to buy right now.
Our Methodology
We sifted through different stock screeners to compile a list of stocks with a short interest between 15% and 25%. We then selected 11 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2025.
Note: All data was sourced on December 9.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
11 High Short Interest Stocks to Buy Right Now
11. The Campbell’s Company (NASDAQ:CPB)
Short % of Float as of November 14: 20.00%
Number of Hedge Fund Holders: 40
The Campbell’s Company (NASDAQ:CPB) is one of the high short interest stocks to buy right now. On December 10, Bernstein lowered the firm’s price target on Campbell’s Company to $33 from $39 and maintained an Outperform rating on the shares. According to Bernstein, the company’s product mix generally aligns with current consumer trends. Their Meals & Beverages division benefits from performance in broths and condensed soups. Premium brands like Pacifico and Rao’s also perform well due to their focus on high-quality ingredients. However, Ready-to-Serve soup is struggling due to the Well Yes! brand discontinuation.
A day prior, on December 9, Campbell’s Company announced its FQ1 earnings beat, with a Non-GAAP EPS of $0.77, surpassing analyst expectations by $0.04. Quarterly revenue reached $2.7 billion, which exceeded forecasts by $40 million, despite representing a 3% year-over-year decline.
In a strategic effort to support the growth of the company’s recently acquired Rao’s sauces brand (which was a deal that closed earlier in 2024), Campbell’s Company has entered into agreements to acquire a 49% interest in La Regina, the producer of the sauces. The company also reaffirmed its full fiscal year 2026 guidance, projecting an adjusted EPS between $2.40 and $2.55.
The Campbell’s Company (NASDAQ:CPB), together with its subsidiaries, manufactures and markets food and beverage products in the US and internationally. It operates through the Meals & Beverages and Snacks segments.
10. Oscar Health Inc. (NYSE:OSCR)
Short % of Float as of November 14: 13.91%
Number of Hedge Fund Holders: 40
Oscar Health Inc. (NYSE:OSCR) is one of the high short interest stocks to buy right now. On November 26, Piper Sandler analyst Jessica Tassan upgraded Oscar Health to Overweight from Neutral with a $25 price target, raised from $13. After a thorough analysis of benefit design, pricing, and broker strategy in Miami-Dade, which is Oscar’s largest county, Tassan believes that Oscar can simultaneously increase market share and profitability, even if the Enhanced Advance Premium Tax Credits/E-APTCs expire at the end of 2025. Piper Sandler views Oscar’s 2027 adjusted EBITDA of $404 million as the minimum expectation.
In its Q3 2025 earnings call, reported earlier the same month, Oscar Health announced a 23% year-over-year increase in total revenue, which reached ~$3 billion. Oscar also reported a strong increase in membership, ending the first 9 months of 2025 with more than 2 million members, which represents a 28% increase compared to the previous year. To enhance its market presence, Oscar Experience is now available in 20 states, including new entries into Alabama and Mississippi.
Additionally, the company is introducing innovative products, such as the Hello Meow plan for women experiencing menopause, and is using its health AI agent, called Oswell, to improve member health management and care paths. Looking ahead, Oscar Health anticipates a contraction in the overall market due to the expected expiration of enhanced premium tax credits and ongoing program integrity efforts. Consequently, the company expects a sequential decline in membership in Q4 due to historical churn patterns and the end of continuous monthly Special Enrollment Periods/SEP for certain income levels.
Oscar Health Inc. (NYSE:OSCR) operates as a healthcare technology company in the US. The company offers health plans to individuals, families, employees, and small group markets.
9. Planet Labs (NYSE:PL)
Short % of Float as of November 14: 13.96%
Number of Hedge Fund Holders: 40
Planet Labs (NYSE:PL) is one of the high short interest stocks to buy right now. On December 4, Clear Street analyst Greg Pendy raised the firm’s price target on Planet Labs to $14 from $12 and kept a Buy rating on the shares. The firm increased its revenue projection for Planet Labs for FY2028 to $445 million, up from a previous estimate of $422 million. In anticipation of the company’s FQ3 2026 earnings report, Clear Street is applying a higher valuation multiple to this raised projection.
In other news, on November 18, Planet Labs Germany GmbH, which is a part of Planet Labs, announced a partnership focused on jointly soliciting customer interest for AI-enabled ‘Tip & Cue’ intelligence solutions, specifically targeting defense customers within Europe. This collaboration aims to enhance efficiency by merging Planet’s wide-area satellite change detection and Very High Resolution/VHR tasking with Quantum Systems’ high-precision reconnaissance solutions.
The primary objective of the joint solutions is to support European defense priorities by using the companies’ existing European footprints to address the urgent need for complementary, action-oriented intelligence. The goal is to move beyond simple data delivery and provide concrete operational value, with the ultimate purpose of helping European nations secure peace and stability. Both companies have already been critical supporters of Ukraine’s defense efforts.
Planet Labs (NYSE:PL) designs, constructs, and launches constellations of satellites with the intent of providing high cadence geospatial data delivered to customers through an online platform in the US and internationally.
8. Mirum Pharmaceuticals Inc. (NASDAQ:MIRM)
Short % of Float as of November 14: 14.91%
Number of Hedge Fund Holders: 42
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the high short interest stocks to buy right now. On December 9, Morgan Stanley analyst Michael Ulz raised the firm’s price target on Mirum Pharmaceuticals to $95 from $81 with an Overweight rating on the shares. Ulz informed investors that the acquisition of Bluejay is significant because it adds the drug brelovitug to the pipeline. Brelovitug has shown promising activity and tolerability in treating hepatitis delta virus and will expand the company’s rare liver disease pipeline while also creating valuable synergies.
In its Q3 2025 earnings report, Mirum Pharmaceuticals’ quarterly revenue totaled $133 million, which marked a ~50% year-over-year increase. This strong performance highlighted the operating leverage in its commercial model, resulting in a positive net income of ~$3 million for the quarter. The primary driver of revenue was the company’s product sales. LIVMARLI net product sales totaled $92 million for the quarter, broken down into $64 million in US sales and $28 million in International sales. Sales of Bile Acid Medicines contributed an additional $41 million in net product sales.
Despite the strong performance, the company faces some commercial variability, particularly with LIVMARLI’s international sales due to periodic large orders from distributors. Management anticipates a sequential decline in revenue for Q4 and does not expect additional sales to its partner, Takeda, in Japan during that quarter, which had contributed to the Q3 revenue. The company is also facing uncertainty regarding the appropriate pricing strategy for its investigational drug, volixibat, as it continues to analyze market dynamics, considering analogs from other PBC treatments.
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is a biopharmaceutical company that develops and commercializes novel therapies for debilitating rare and orphan diseases.
7. MP Materials Corp. (NYSE:MP)
Short % of Float as of November 14: 15.23%
Number of Hedge Fund Holders: 42
MP Materials Corp. (NYSE:MP) is one of the high short interest stocks to buy right now. On December 5, Morgan Stanley upgraded MP Materials to Overweight from Equal Weight with a price target of $71, up from $68.5. Morgan Stanley believes that the US’s critical mineral dependency issues are not resolved by China’s one-year pause on rare earth restrictions. As the US seeks to develop a robust supply chain outside of China, MP is well-positioned to benefit.
Earlier in the company’s Q3 2025 earnings report, MP Materials Corp highlighted record production and key strategic advancements. The company achieved a record NDPR oxide production of 721 metric tons, which marked a 21% sequential increase and a 51% year-over-year increase. MP also set records in sales volumes, showing strong sequential and year-over-year growth. MP Materials is on track to start commissioning its heavy rare earth circuit in mid-2026. This initiative will enable the production of 10,000 metric tons of high-performance NDFEB magnets annually.
Additionally, a major partnership with Apple (NASDAQ:AAPL) has commenced, marked by a $40 million prepayment for the production of magnets from recycled materials, with a total of $200 million expected as the project progresses. The company anticipates the next payment from Apple in Q4, with initial magnet volumes targeting mid-2027 and recycling shortly after. This partnership, alongside the long-term Purchase Price Agreement with the Department of War, provides earnings visibility and is expected to help the company return to profitability in Q4 2025.
MP Materials Corp. (NYSE:MP), together with its subsidiaries, produces rare earth materials in the Western Hemisphere. The company operates in two segments: Materials and Magnetics.
6. Moderna Inc. (NASDAQ:MRNA)
Short % of Float as of November 14: 20.02%
Number of Hedge Fund Holders: 42
Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that it had secured a five-year loan of $1.5 billion from Ares Management Corp (NYSE:ARES). The company made this announcement as it prepared to unveil strategy updates to analysts later that day. Moderna plans to draw $600 million upfront and retains optional access to an additional $400 million through November 2027 and $500 million through November 2028.
President of Moderna, Stephen Hoge, noted that the loan provides the company with flexibility to fund business development opportunities or manage risk. Moderna is targeting up to 10% revenue growth in 2026, following financial struggles since the collapse of COVID-19 vaccine demand. The company’s revenue fell from $18.4 billion in 2022 to a fraction of that, which forced deep cost cuts and pipeline reprioritization. Moderna now expects sales between $1.6 and $2 billion for 2025.
The projected 10% revenue growth for 2026 is contingent upon momentum from partnerships in the UK, Canada, and Australia, along with US demand for its next-generation COVID vaccine, mNEXSPIKE. Further revenue lifts are anticipated in 2027 as Pfizer’s EU COVID vaccine deal expires, opening national tenders in a $1.8 billion market where Moderna currently has minimal share. Additional growth is expected in 2028 from the anticipated rollouts of its COVID-flu combination shot and a norovirus vaccine, products which Moderna expects to be the first and potentially only player to offer in those categories.
Moderna Inc. (NASDAQ:MRNA) is a biotechnology company that provides messenger RNA medicines in the US, Europe, and internationally.
5. Dyne Therapeutics Inc. (NASDAQ:DYN)
Short % of Float as of November 14: 13.37%
Number of Hedge Fund Holders: 45
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now. On December 8, Dyne Therapeutics announced positive topline results from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial. The trial is evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy/DMD amenable to exon 51 skipping.
The DELIVER trial also provided new positive long-term clinical data from its ongoing open-label extension and long-term extension portions. Z-rostudirsen is an investigational therapeutic using Dyne’s FORCE platform, designed to enable the production of near full-length dystrophin by conjugating a phosphorodiamidate morpholino oligomer to an antigen-binding fragment that binds to the transferrin receptor 1.
The drug has received Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the US FDA, as well as Orphan Drug designation from the FDA, EMA, and MHLW in Japan. The REC met its primary endpoint and showed a statistically significant increase in muscle content-adjusted dystrophin expression to 5.46% of normal relative to baseline at 6 months. Functional improvement was observed across all 6 prespecified clinical endpoints at 6 months relative to baseline and declines in the pooled placebo group. Dyne is on track to submit a Biologics License Application/BLA for US Accelerated Approval in Q2 2026.
Dyne Therapeutics Inc. (NASDAQ:DYN) is a clinical-stage neuromuscular disease company that discovers and develops therapeutics for neuromuscular diseases in the US.
4. Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL)
Short % of Float as of November 14: 19.26%
Number of Hedge Fund Holders: 48
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals to $620 from $568 and maintained a Buy rating. H.C. Wainwright increased its assumptions for Rezdiffra penetration after consulting with 6 key opinion leaders/KOLs. They reported real-world uptake of the drug among patients with metabolic dysfunction-associated steatohepatitis/MASH who have F2/F3 liver fibrosis. Despite competitive pressure from weight loss medications, the firm noted that the KOLs view Rezdiffra as an effective, liver-directed, oral backbone therapy that offers broader expansion possibilities based on forthcoming F4c data.
Earlier in its Q3 2025 earnings call, Madrigal Pharmaceuticals reported significant commercial momentum for its product, Rezdiffra. The company achieved net sales of $287.3 million for the quarter, marking a 35% sequential increase. The total number of patients on Rezdiffra therapy has surpassed 29,500, up from over 23,000 in the previous quarter, with more than 10,000 healthcare providers having prescribed the medication.
Madrigal has made substantial progress in securing market access, achieving broad first-line access with no step edit requirements in its payer contracting for 2026. Adherence rates for Rezdiffra are stable, similar to other well-tolerated oral medications, ranging from 60% to 70%. Madrigal is also focused on expanding its global presence, having successfully launched Rezdiffra in Germany following European approval. However, the impact of the EU launch on 2026 growth is expected to be modest, with the majority of growth still driven by the US market.
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is a biopharmaceutical company that delivers novel therapeutics for metabolic dysfunction-associated steatohepatitis/MASH in the US.
3. Wayfair Inc. (NYSE:W)
Short % of Float as of November 14: 20.72%
Number of Hedge Fund Holders: 50
Wayfair Inc. (NYSE:W) is one of the high short interest stocks to buy right now. On December 9, Jefferies analyst Jonathan Matuszewski maintained a Hold rating on Wayfair with a $94 price target.
Earlier on December 3, Jefferies downgraded Wayfair to Hold from Buy with the same unchanged price target of $94. The firm cited a slowdown in Wayfair’s holiday shopping season based on web traffic analysis and consumer survey data, indicating a lower propensity for future purchases. Jefferies believes that the stock’s risk/reward profile is now more balanced. Consequently, the upside valuation case for the company has become less certain.
In Q3 2025, Wayfair reported a total net revenue reached $3.1 billion, which marked an 8.1% increase year-over-year, or 9% when excluding the impact of the company’s exit from the German market. US net revenue was $2.7 billion, up 8.6%, while International net revenue was $389 million, up 4.6%. However, the company also reported a net loss of $99 million (diluted loss per share of $0.76), though this improved from the $74 million net loss in the same period in 2024.
The Average order value rose to $317 in Q3, up from $310 in the same quarter last year. Repeat customers placed 80.1% of total orders delivered, up from 79.9% in Q3, representing 7.9 million orders, an increase of 6.8%. Orders placed via a mobile device accounted for 63.0% of total orders delivered. Despite the growth in orders, active customers totaled 21.2 million as of September 30, a decrease of 2.3% year-over-year.
Wayfair Inc. (NYSE:W) engages in the e-commerce business in the US and internationally. It offers online selections of furniture, décor, housewares, and home improvement products through its sites, comprising Wayfair, Joss & Main, AllModern, Birch Lane, Perigold, and Wayfair Professional.
2. Lyft Inc. (NASDAQ:LYFT)
Short % of Float as of November 14: 16.66%
Number of Hedge Fund Holders: 51
Lyft Inc. (NASDAQ:LYFT) is one of the high short interest stocks to buy right now. On December 9, Wells Fargo raised the firm’s price target on Lyft to $26 from $20, while maintaining an Equal Weight rating on the shares. Wells Fargo acknowledged that because Lyft is primarily a US rideshare operator, its positive outlook for the US rideshare market in 2026 is a clear benefit to the stock. However, the firm is maintaining a neutral stance because it views Lyft’s recent diversification into non-US assets as a move that will negatively impact both its valuation multiple and its growth rate.
In Q3 2025, Lyft achieved 10.67% year-over-year growth in its quarterly revenue, which totaled $1.69 billion but missed expectations by $13.18 million. The company also earned $0.30 per share, although this number missed Street estimates by $0.01. The quarter saw new record highs in Driver Hours, Active Riders, and Gross Bookings. Market demand remained robust, evidenced by a record 18% increase in Active Riders and a 16% increase in Gross Bookings. A significant portion of this growth came from areas the company considers underpenetrated, with 70% of ride growth in Q3 originating from these markets.
Lyft is executing several strategic initiatives. Its partnership with United Airlines is now live, enabling users to earn miles on eligible rides, which is expected to enhance customer loyalty. The company has also expanded its AV partnerships, including collaborations with Waymo and Tensor, powered by NVIDIA (NASDAQ:NVDA), positioning Lyft across the AV value chain. Furthermore, acquisitions like Free Now in Europe and TBR Global Chauffeuring are intended to double Lyft’s TAM and expand its global presence and high-value service offerings.
Lyft Inc. (NASDAQ:LYFT) operates a peer-to-peer marketplace for on-demand ridesharing in the US and Canada. The company operates multimodal transportation networks that offer access to various transportation options through the Lyft platform and mobile-based applications.
1. Lumentum Holdings Inc. (NASDAQ:LITE)
Short % of Float as of November 14: 18.18%
Number of Hedge Fund Holders: 69
Lumentum Holdings Inc. (NASDAQ:LITE) is one of the high short interest stocks to buy right now. On December 5, JPMorgan analyst Samik Chatterjee raised the firm’s price target on Lumentum to $350 from $235, while keeping an Overweight rating on the shares. This sentiment was posted as JPMorgan broadly increased its financial estimates for optical companies, citing new opportunities in scale-across and multi-rail. The firm explained that the extra market potential from scale-across and the new telecom products supporting multi-rail infrastructure in long-haul and metro networks create a stronger outlook.
Earlier, for FQ1 2026, Lumentum Holdings announced the highest quarterly revenue in the company’s history. Total revenue reached $533.8 million, which marked a 58% year-over-year increase. AI and cloud infrastructure account for over 60% of its revenue. Segment revenue breakdown showed components revenue at $379.2 million, growing 18% sequentially and 64% year-over-year. Systems revenue was $154.6 million, which declined 4% sequentially but was still up 47% year-over-year.
However, despite the growth, Lumentum faces a supply-demand imbalance, with demand outstripping supply by 25% to 30%. The company is allocating supply and using this imbalance to implement targeted price increases, with broader pricing adjustments anticipated in 2026. For FQ2, Lumentum expects total revenue between $630 and $670 million. The company also expressed increased confidence in the Optical Circuit Switch market, aiming to reach $100 million in quarterly revenue by December 2026.
Lumentum Holdings Inc. (NASDAQ:LITE) manufactures and sells optical and photonic products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. It operates through two segments: Cloud & Networking and Industrial Tech.
While we acknowledge the potential of LITE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LITE and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
